市場調查報告書

皮膚癌診斷及治療藥的全球市場 - 成長,趨勢,預測(2018年∼2023年)

Skin Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 708645
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
Back to Top
皮膚癌診斷及治療藥的全球市場 - 成長,趨勢,預測(2018年∼2023年) Skin Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年07月01日內容資訊: 英文 112 Pages
簡介

全球皮膚癌診斷及治療藥市場在2018年到2023年間,預測將以9.2%的年複合成長率擴大。

本報告提供皮膚癌診斷及治療藥的全球市場調查,提供市場概要,各類型,各地區的市場趨勢,市場規模的變化與預測,市場促進·阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品與服務的威脅
    • 產業內的競爭

第6章 市場動態

  • 市場成長要素
  • 市場阻礙因素
  • 市場機會
  • 市場課題

第7章 市場區隔

  • 各類型
    • 基底細胞癌
    • 扁平表皮細胞癌症
    • 黑色素瘤
  • 各流程
    • 診斷
    • 治療
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第8章 企業簡介

  • Abbott Inc.
  • Agilent Technologies Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pfizer Inc.
  • Qiagen NV
  • F. Hoffmann-La Roche AG
  • Sanofi SA

第9章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 64187

Market Overview

The global skin cancer diagnostics and therapeutics market are expected to witness a CAGR of 10.4% over the forecast period. Certain factors driving the market growth include increasing incidence of skin cancer, extensive R&D pipelines, and rising awareness about skin cancer.

Skin cancer is the most common form of cancer. Even though most types of skin cancers are preventable, its incidence is increasing. People can recognize changes in their skin during the early stages of the disease. The risk factors include sunlight, sunlamps and tanning booths, certain medical conditions, or medicines. The UV radiation changes the genetic material (DNA) in cells and is, therefore, the main cause of skin cancer. According to the American Cancer Society, exposure to the sun is the most preventable risk factor for all skin cancers. The rate of new melanoma cases among both men and women has been increasing at 1.7% and 1.4% per year respectively, as per the data of Federal Centers for Disease Control and Prevention (CDC). Thus, the increasing prevalence of skin cancer is augmenting the growth of the market studied.

However, a common side effect of radiation therapy is skin irritation in the area of the body that is being treated. The skin reaction can range from mild redness and dryness (similar to a sunburn) to severe peeling (desquamation) of the skin in some patients. The majority of skin reactions to radiation therapy go away a few weeks after the treatment is completed. In some cases, the treated skin will remain slightly darker than it was before and may continue to be more sensitive to sun exposure. About two to three weeks after first radiation treatment, redness is noticed and irritation is similar to a sunburn. The skin may be itchy, dry, red, or sore. There are also long-term side effects, like changes in skin color, lung problems, and others, which act as major restraints for the growth of the market studied.

Scope of the Report

Ultraviolet radiation is a primary carcinogen that results in UV induced mutations, loss of activity in tumor suppressor genes, and the overexpression of oncogenes in keratinocytes, thus boosting the development of skin malignancies. The skin cancer diagnostics and therapeutics market comprise of various diagnostics and therapies related to skin cancer.

Key Market Trends

Non-melanoma is expected to hold a Significant Market Share in the Disease Type

According to the ASCO (American Society of Clinical Oncology), it is estimated that more than 3 million people in the United States are diagnosed with non-melanoma skin cancer each year. Basal cell carcinoma is far more common than squamous cell carcinoma. About 80% of non-melanoma skin cancer is basal cell carcinoma. Similarly, the CCS (Canadian Cancer Society) states that non-melanoma skin cancer is the most common cancer diagnosed among Canadians. It makes up at least 40% of all new cancer cases in Canada.

Furthermore, it has been stated by the National Institute of Health that there were around 948 deaths observed during the year 2017 due to non-melanoma skin cancer in Japan. Similarly, Australia is also facing the burden of non-melanoma skin cancer deaths. Cancer Council has stated that around 679 deaths were noted during the year 2016-2027 due to this cancer in Australia.

Above mentioned statistics indicate that non-melanoma skin cancer is showing considerable mortality across the major countries in the globe which in turn is augmenting the demand for better treatment.

North America dominates the market and expected to do Same in the Forecast Period

North America is expected to dominate the market in the forecast period. As per the American Academy of Dermatology, skin cancer is the most common cancer in the United States. Most cases of melanoma, the deadliest kind of skin cancer, are caused by exposure to ultraviolet (UV) light. It is estimated that approximately 9,500 people in the United States are diagnosed with skin cancer every day. Thus, the increasing incidences of skin cancer in the region is a major factor driving the growth of the market studied. Additionally, the recent advancements of skin cancer therapy, including photodynamic therapy (PDT), have been widely used in treating non-melanoma skin malignancies, thus boosting the growth of the market studied during the forecast period.

Competitive Landscape

The global skin cancer diagnostics and therapeutics market is highly competitive and consists of a number of major players. Companies, like Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., among others, hold the substantial market share in the skin cancer therapeutics market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Skin Cancer
    • 4.2.2 Rising Awareness About Skin Cancer
    • 4.2.3 Extensive R&D Pipelines
  • 4.3 Market Restraints
    • 4.3.1 High Cost Associated with Therapy
    • 4.3.2 Stringent Regulatory Environment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Disease Type
    • 5.1.1 Melanoma
    • 5.1.2 Non-melanoma
  • 5.2 By Diagnosis
    • 5.2.1 Dermatoscopy
    • 5.2.2 Skin Biopsy
    • 5.2.3 Lymph Node Biopsy
    • 5.2.4 Imaging Tests
    • 5.2.5 Blood Tests
    • 5.2.6 Others
  • 5.3 By Treatment
    • 5.3.1 Chemotherapy
    • 5.3.2 Photodynamic Therapy
    • 5.3.3 Immunotherapy
    • 5.3.4 Targeted Therapy
    • 5.3.5 Surgery
    • 5.3.6 Radiation Therapy
    • 5.3.7 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Inc.
    • 6.1.2 Amgen, Inc.
    • 6.1.3 AstraZeneca PLC
    • 6.1.4 Bristol-Myers Squibb Company
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 GlaxoSmithKline Plc
    • 6.1.7 Merck & Co., Inc.
    • 6.1.8 Novartis AG
    • 6.1.9 Qiagen NV
    • 6.1.10 Sun Pharmaceutical Industries Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top